LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing
Adipose stem cells (ASCs) have attracted considerable attention as potential therapeutic agents due to their ability to promote tissue regeneration. However, their limited tissue repair capability has posed a challenge in achieving optimal therapeutic outcomes. Herein, we conceive a series of lipid nanoparticles to reprogram ASCs with durable protein secretion capacity for enhanced tissue engineering and regeneration. In vitro studies identify that the isomannide-derived lipid nanoparticles (DIM1T LNP) efficiently deliver RNAs to ASCs. Co-delivery of self-amplifying RNA (saRNA) and E3 mRNA complex (the combination of saRNA and E3 mRNA is named SEC) using DIM1T LNP modulates host immune responses against saRNAs and facilitates the durable production of proteins of interest in ASCs. The DIM1T LNP-SEC engineered ASCs (DS-ASCs) prolong expression of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 12 (CXCL12), which show superior wound healing efficacy over their wild-type and DIM1T LNP-mRNA counterparts in the diabetic cutaneous wound model. Overall, this work suggests LNPs as an effective platform to engineer ASCs with enhanced protein generation ability, expediting the development of ASCs-based cell therapies.
Top-30
Journals
|
1
2
3
|
|
|
Advanced Materials
3 publications, 5.26%
|
|
|
Nano Research
2 publications, 3.51%
|
|
|
Advanced healthcare materials
2 publications, 3.51%
|
|
|
Nature Communications
2 publications, 3.51%
|
|
|
Chemical Engineering Journal
2 publications, 3.51%
|
|
|
eLife
2 publications, 3.51%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 1.75%
|
|
|
Nature Reviews Bioengineering
1 publication, 1.75%
|
|
|
Journal of Liposome Research
1 publication, 1.75%
|
|
|
BioNanoScience
1 publication, 1.75%
|
|
|
Bioengineering & Translational Medicine
1 publication, 1.75%
|
|
|
International Journal of Biological Macromolecules
1 publication, 1.75%
|
|
|
Biomarker Research
1 publication, 1.75%
|
|
|
Trends in Biotechnology
1 publication, 1.75%
|
|
|
Scientific Reports
1 publication, 1.75%
|
|
|
Advanced Science
1 publication, 1.75%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 1.75%
|
|
|
Biomaterials Science
1 publication, 1.75%
|
|
|
Nano Letters
1 publication, 1.75%
|
|
|
Russian Chemical Reviews
1 publication, 1.75%
|
|
|
ACS Nano
1 publication, 1.75%
|
|
|
Molecular Therapy
1 publication, 1.75%
|
|
|
Biomolecules
1 publication, 1.75%
|
|
|
Industrial Crops and Products
1 publication, 1.75%
|
|
|
Matter
1 publication, 1.75%
|
|
|
ACS Sustainable Resource Management
1 publication, 1.75%
|
|
|
Nature Materials
1 publication, 1.75%
|
|
|
Cellular and Molecular Biology Letters
1 publication, 1.75%
|
|
|
Macromolecular Rapid Communications
1 publication, 1.75%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
12
14
16
18
|
|
|
Elsevier
17 publications, 29.82%
|
|
|
Wiley
13 publications, 22.81%
|
|
|
Springer Nature
11 publications, 19.3%
|
|
|
American Chemical Society (ACS)
4 publications, 7.02%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 5.26%
|
|
|
Taylor & Francis
2 publications, 3.51%
|
|
|
eLife Sciences Publications
2 publications, 3.51%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 1.75%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.75%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 1.75%
|
|
|
MDPI
1 publication, 1.75%
|
|
|
Tsinghua University Press
1 publication, 1.75%
|
|
|
2
4
6
8
10
12
14
16
18
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.